Product image of Nitisinon Dipharma (Nitisinone) supplied by GNH India

Nitisinon Dipharma

Active Ingredient:
Nitisinone
Origin:
EU

Nitisinon Dipharma (Nitisinone)

Nitisinone, the active ingredient in Nitisinon Dipharma, is a tyrosine metabolism inhibitor presented as an oral dosage form for oral use. It treats hereditary tyrosinemia type I in patients with the condition.

GNH India supplies Nitisinon Dipharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Dipharma Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Nitisinone acts on the tyrosine degradation pathway to manage hereditary tyrosinemia type I.
  • Hereditary tyrosinemia type I: reduces accumulation of toxic metabolites and improves liver function.
  • Hereditary tyrosinemia type I (pre‑transplant): helps stabilize metabolic status to allow safe liver transplantation.
  • Hereditary tyrosinemia type I (post‑transplant): maintains metabolic control and reduces risk of disease recurrence.

How It Works

  • Nitisinone inhibits the enzyme 4‑hydroxyphenylpyruvate dioxygenase (HPPD), a key step in the catabolism of tyrosine. By blocking HPPD, the drug prevents formation of downstream toxic metabolites such as fumarylacetoacetate, thereby reducing hepatic and renal damage associated with hereditary tyrosinemia type I.

Side Effects

Nitisinone may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nausea: occasional, may improve with food.
  • Abdominal pain: intermittent discomfort.
  • Fatigue: generalized tiredness.
  • Skin rash: erythematous or pruritic lesions.
  • Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects

  • Hepatic failure: severe liver dysfunction requiring monitoring.
  • Severe anemia: marked reduction in hemoglobin.
  • Neutropenia: low neutrophil count increasing infection risk.
  • Peripheral neuropathy: tingling or numbness in extremities.
  • Hypersensitivity reactions: including angioedema or anaphylaxis.

Precautions & Warnings

  • Before initiating therapy, clinicians should consider several safety measures.
  • Monitor liver function: obtain baseline and periodic transaminase levels.
  • Assess renal function: evaluate creatinine clearance and adjust if necessary.
  • Avoid use in patients with known hypersensitivity to nitisinone or excipients.
  • Use caution in pregnancy: potential risks are not well defined.
  • Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Nitisinone can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Warfarin: may potentiate anticoagulant effect and increase bleeding risk.
  • Strong CYP450 inducers (e.g., rifampicin, carbamazepine): can lower nitisinone plasma concentrations.
  • Other HPPD inhibitors: additive toxicity to the tyrosine pathway.

Moderate Interactions (Monitor Closely)

  • Acetaminophen: monitor liver enzymes for potential hepatotoxicity.
  • NSAIDs: watch renal function, especially in patients with pre‑existing kidney disease.
  • Anticonvulsants (e.g., phenytoin): may alter nitisinone metabolism; check therapeutic levels.

Frequently Asked Questions

Nitisinon Dipharma contains nitisinone, which is prescribed to treat hereditary tyrosinemia type I, a rare metabolic disorder that causes accumulation of toxic tyrosine metabolites and can lead to liver and kidney damage.

Nitisinone blocks the enzyme 4‑hydroxyphenylpyruvate dioxygenase (HPPD) in the tyrosine degradation pathway. This inhibition prevents the formation of harmful downstream metabolites, thereby reducing liver and renal toxicity in patients with hereditary tyrosinemia type I.

The specific dose of Nitisinon Dipharma is determined by the prescribing physician based on the patient’s age, weight, disease severity, and clinical response. Dosing should follow the healthcare professional’s instructions and not be altered without medical advice.

Safety data for nitisinone in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitisinone is the primary disease‑modifying therapy for hereditary tyrosinemia type I, directly targeting the metabolic defect. Alternative approaches, such as liver transplantation, address organ failure but do not correct the underlying metabolic pathway. Nitisinone therefore offers a less invasive, long‑term management option.

Nitisinon Dipharma should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and sources of heat to maintain its stability.

The medication is taken orally, usually with water. The exact administration schedule—such as frequency and timing relative to meals—must be prescribed by a healthcare professional and adhered to for optimal therapeutic effect.

Serious risks include hepatic failure, severe anemia, neutropenia, peripheral neuropathy, and hypersensitivity reactions such as anaphylaxis. Patients should be monitored regularly for liver function, blood counts and any signs of allergic response.

Individuals with a known hypersensitivity to nitisinone or any of its excipients should avoid the product. Caution is also advised for patients with pre‑existing severe liver disease, uncontrolled infections, or those for whom the risk–benefit profile is unfavorable, as determined by their physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nitisinone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT